Skip to main content

Zentalis Pharmaceuticals, Inc.

corporate_fare Company Profile

Zentalis Pharmaceuticals, Inc.

ZNTL·NASDAQ·Life Sciences·CIK 0001725160

The company is a clinical-stage biopharmaceutical company focused on developing azenosertib (ZN-c3), an investigational WEE1 inhibitor, for patients with ovarian cancer and other tumor types. Azenosertib has demonstrated anti-tumor activity as a single agent across multiple tumor types in clinical trials. The company is currently advancing the clinical development of azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The DENALI (ZN-c3-005) Part 2 clinical trial of azenosertib in patients with Cyclin E1-positive PROC, if successful, may support an accelerated approval, subject to U.S. Food and Drug Administration (FDA) review. The company exclusively in-licenses or solely owns worldwide development and commercialization rights to azenosertib. Its strategy includes rapidly advancing azenosertib as a monotherapy toward first regulatory approval in Cyclin E1-positive PROC. In January 2025, clinical data showed an objective response rate (ORR) of over 30% and a manageable safety profile in patients with Cyclin E1-positive PROC who received azenosertib at 400 mg QD 5:2. Enrollment in Part 2a of the Phase 2 DENALI clinical trial was completed in 2025, with a topline readout anticipated by year end 2026. The company also plans to advance the development of azenosertib outside of Cyclin E1-positive PROC, as resources allow.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ZNTL at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Zentalis' Azenosertib Shows Preclinical Efficacy in Triple-Negative Breast Cancer and Validates Ovarian Cancer Unmet Need
  • Zentalis Selects Optimal Dose for Pivotal Ovarian Cancer Trial, Advancing Azenosertib
  • Zentalis Pharmaceuticals Reports Strong Financial Position, Extended Cash Runway, and Key Clinical Progress for Azenosertib
  • Zentalis' Azenosertib Advances: FDA Aligns on Phase 3, DENALI Readout Expected for Accelerated Approval
  • Zentalis Pharmaceuticals Advances Azenosertib to Phase 3 with FDA Alignment and Extends Cash Runway Beyond Market Cap

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$137.06M
Diluted EPS
-$1.91
Op. Cash Flow
-$125.25M
Free Cash Flow
-$125.25M
Operating Income
-$152.81M
Cash & Equivalents
$35.99M
Debt / Equity
0.00×
Shares Outstanding
69.09M sh
Source: 10-K · filed 2026-03-26 · accession 0001725160-26-000014
$1.38 +1.47% today
52-week range · as of 2026-11-09 $1.21 – $6.95
Market cap
$133.64M
Volume
1.5M (1.1× avg)
3-mo avg 1.4M
Live data · 2026-11-21 19:24 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ZNTL - Filings & News (Page 2)

ZNTL
Apr 17, 2026, 3:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.49
Real-time Price: $1.38 info
Change: -$3.11 (-69%) info
Market Cap: $133.642M info
ZNTL
Apr 09, 2026, 8:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.76
Real-time Price: $1.38 info
Change: -$1.38 (-50%) info
Market Cap: $133.642M info
ZNTL
Mar 26, 2026, 4:46 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.60
Real-time Price: $1.38 info
Change: -$1.22 (-47%) info
Market Cap: $133.642M info
ZNTL
Mar 26, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.67
Real-time Price: $1.38 info
Change: -$1.29 (-48%) info
Market Cap: $133.642M info
ZNTL
Jan 09, 2026, 5:18 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.08
Real-time Price: $1.38 info
Change: -$2.70 (-66%) info
Market Cap: $133.642M info
ZNTL
Jan 08, 2026, 4:57 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $2.82
Real-time Price: $1.38 info
Change: -$1.44 (-51%) info
Market Cap: $133.642M info
ZNTL
Jan 02, 2026, 4:14 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Price at Filing: $1.37
Real-time Price: $1.38 info
Change: +$0.0100 (+0.73%) info
Market Cap: $133.642M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets